In a CotW a few weeks ago we postulated that based on biomarker discovery work Celgene is poised to dominate personalized medicine. However, this week’s chart suggests that if Celgene’s rise in personalized medicine is to happen it could be a long ways off. Other big pharma are getting biomarkers to market faster.
Share this Image On Your Site
<p><strong>Please include attribution to amplion.com with this graphic.</strong><br /><br /><a href=”><img src=’https://amplion.com/wp-content/uploads/2016/04/innovative_company_comparison_point.png’ alt=’Innovative Pharma Comparison’ width=’540px’ border=’0′ /></a></p>
Do you need similar analysis?
[plsc_button url=”https://amplion.wpengine.com/consulting?hsCtaTracking=0ecabe42-acda-48e9-b2bd-1a020165bdb3%7Cb6240f02-690a-44c9-8446-a7209594c70a” target=”_blank” color=”green” style=”flat” radius=”square” size=”lg”]TALK TO A CONSULTANT[/plsc_button]